Physician profile
John A Holets
NPI 1427051275
$10,662.89
in general payments reported to CMS, 2019-2025
45 companies · $1,980 in 2025
The $1,980 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $995 · 2021: $1,602 · 2022: $1,562 · 2023: $1,866 · 2024: $2,074 · 2025: $1,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,920.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,682.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,455.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $977.81 | 2019-2025 | |
| Amgen INC. | $769.57 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $704.06 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $670.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $581.50 | 2019-2024 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $351.77 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $330.62 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $297.41 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.52 | 2021-2025 | |
| Abbott Laboratories | $290.00 | 2021-2024 | Proclaim |
| Lundbeck LLC | $279.79 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $252.97 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Esperion Therapeutics, INC. | $235.48 | 2020-2025 | Nexletol |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Holets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.